Intracranial neoplasms can arise from any of the structures or cell types present in the cranial vault, including the brain, meninges, pituitary gland, skull, and even residual embryonic tissue. The overall annual incidence of primary brain tumors in the United States is 14 cases per 100,000 population. More »
Nationally recognized breast cancer specialist Eric P. Winer, MD, presented two lectures at this year’s MBCC, “Strategies for Patients with Refractory HER2-Positive Breast Cancer,” and “Addressing Menopausal Symptoms and Fertility in Breast Cancer.” In an exclusive interview with ONCOLOGY, Dr. Winer explained how hormonal therapy can best be used in the difficult stetting of metastatic disease. More »
Magnets have been thought for centuries to have healing power. Scientists at Georgia Institute of Technology and the Ovarian Cancer Institute hope to take this possibility a quantum leap further. They are grooming magnetic nanoparticles as the mainstay of a technique aimed at filtering out free-circulating ovarian cancer cells from the body. Their goal is to slow or stop the metastatic spread of cancer. More »
Multi-targeted TKI inhibitors are gaining traction in the treatment of advanced breast cancer, although results from four different trials do show varying degrees of efficacy. More »
The targeted combination of lapatinib (Tykerb) plus trastuzumab (Herceptin) led to a median overall survival of 14 months in women with refractory metastatic breast cancer. More »
As many as one in four cancer patients develop metastatic cancers of the brain. Existing therapies seldom do more than slow the disease. Adding to the urgency to find a way to prevent brain metastasis is the increasing number of such cases. More »
More than 50% of patients with advanced breast or prostate cancer have identifiable bone metastasis, and 30% to 40% of patients with non–small-cell lung cancer ultimately develop metastases to bone.[1,2] More »
The RIBBON-2 trial met its primary endpoint to prolong progression-free survival, making the bevacizumab-chemotherapy combination a new treatment option, said principal investigator Adam Brufsky, MD. The trial continued the evaluation of bevacizumab plus chemotherapy to treat metastatic breast cancer after previous treatment failures. More »
Key Differences between FQHCs and RHCs Chastity Werner, RHIT, June 13, 2013 FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice Susanne Madden, June 12, 2013 Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices Ericka L. Adler, June 12, 2013 Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
iPad Alternatives for Mobile Physicians Marisa Torrieri, June 11, 2013 As more physicians are seeing the merits of media tablets, the market is expanding, too.
